Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Intelligent Medicine Acquisition Corp.IQMD · Entity 11509 | Director | November 04, 2021 | November 04, 2021 |
| SelectQuote, Inc.SLQT · Entity 6791 | Director | November 11, 2025 | November 14, 2025 |
| Sigilon Therapeutics, Inc.SGTX · Entity 11481 | Director | August 11, 2023 | August 11, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Intelligent Medicine Acquisition Corp.
Report date November 04, 2021 · Filed November 04, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-11-04 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: As described in the issuer's registration statement on Form S-1 (File No. 333-260205) under the heading "Description of Securities--Founder Shares", the shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis (subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like) and subject to certain anti-dilution rights and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the issuer's registration statement on Form S-1 (File No. 333-260205) under the heading "Description of Securities--Founder Shares", the shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis (subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like) and subject to certain anti-dilution rights and have no expiration date.
SelectQuote, Inc.
Report date November 11, 2025 · Filed November 14, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.01 per shareSEC Table I · non-derivative | Direct | 363,214 |
Reported balance
After 2025-11-11 transaction · row 1
1 source rowRow 1 · 2025-11-11 · Exercise / conversion · Acquired 52,631 · Balance 363,214 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-11-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-11-11 · Exercise / conversion · Disposed 52,631 · Balance 0 F1: Represents restricted stock units of SelectQuote, Inc. (the "Company") granted to the recipient pursuant to the Company's 2020 Omnibus Incentive Plan. F2: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock, par value $0.01 per share. F3: The award vested in full on the transaction date shown in Column 3. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2035-11-11 | Direct | 106,250 |
Reported balance
After 2025-11-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-11-11 · Grant · Acquired 106,250 · Balance 106,250 F1: Represents restricted stock units of SelectQuote, Inc. (the "Company") granted to the recipient pursuant to the Company's 2020 Omnibus Incentive Plan. F2: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock, par value $0.01 per share. F4: The award vests in full on the date of the Company's 2026 Annual Meeting of Stockholders (the "Vesting Date"), subject to the recipient's continued service on the Company's Board of Directors as of the Vesting Date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units of SelectQuote, Inc. (the "Company") granted to the recipient pursuant to the Company's 2020 Omnibus Incentive Plan.
F2: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock, par value $0.01 per share.
F3: The award vested in full on the transaction date shown in Column 3.
F4: The award vests in full on the date of the Company's 2026 Annual Meeting of Stockholders (the "Vesting Date"), subject to the recipient's continued service on the Company's Board of Directors as of the Vesting Date.
Sigilon Therapeutics, Inc.
Report date August 11, 2023 · Filed August 11, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.28 · Expires 2033-05-18 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-08-11 · Disposition to issuer · Disposed 683 · Balance 0 F1: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split. F2: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.92 · Expires 2032-05-25 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-08-11 · Disposition to issuer · Disposed 683 · Balance 0 F1: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split. F2: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split.
F2: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Arcellx, Inc.
Report date April 28, 2026 · Filed April 28, 2026
Section 16 reporting ended · disclosed 2026-04-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.66 · Expires 2031-12-07 | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-28 · Disposition to issuer · Disposed 27,077 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2032-02-03 | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-28 · Disposition to issuer · Disposed 20,513 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.94 · Expires 2033-06-14 | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-28 · Disposition to issuer · Disposed 11,459 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.30 · Expires 2034-05-28 | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-28 · Disposition to issuer · Disposed 8,011 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.68 · Expires 2035-05-29 | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-04-28 · Disposition to issuer · Disposed 9,174 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger.
TESARO, Inc.
Report date January 22, 2019 · Filed January 22, 2019
Section 16 reporting ended · disclosed 2019-01-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 1
1 source rowRow 1 · 2019-01-22 · Other · Disposed 2,757 · Balance 0 F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement"). |
| Director Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-01-22 · Disposition to issuer · Disposed 4,052 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F3: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. |
| Director Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.03 · Expires 2026-03-31 | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-01-22 · Disposition to issuer · Disposed 24,000 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. |
| Director Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $149.22 · Expires 2027-06-01 | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-01-22 · Disposition to issuer · Disposed 12,000 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. |
| Director Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.89 · Expires 2028-06-01 | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-01-22 · Disposition to issuer · Disposed 7,209 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. |
Filing footnotes · ownership attribution and instrument terms
F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement").
F2: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock.
F3: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share.
F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]
F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 15, 2022 Filed Nov 17, 2022 23:49 UTC | SelectQuote, Inc. SLQT · Entity 6791 | Exercise / conversionCommon Stock, par value $0.01 per share | 7,849 | $0.00 | $0.00 |
DisclosureSEC source: 0001794783-22-000102 · wf-form4_166872895029371.xml · nonDerivative · entry 1 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,568 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 26, 2022 Filed May 27, 2022 21:01 UTC | Sigilon Therapeutics, Inc. SGTX · Entity 11481 | GrantStock Option (Right to Buy) · Derivative | 8,888 | $0.00 Strike: $0.76 | $0.00 |
DisclosureSEC source: 0001415889-22-005828 · form4-05272022_050519.xml · derivative · entry 1 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,888 Underlying: Common Stock · 8,888 shares Expires 2032-05-25 F1 · derivative.exercise_date: The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 100% on May 26, 2023. Read SEC document |
| February 03, 2022 Filed Feb 7, 2022 23:02 UTC | Arcellx, Inc. ACLX · Entity 15294 | GrantStock Option (right to buy) · Derivative | 61,538 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001209191-22-007573 · doc4.xml · derivative · entry 1 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,538 Underlying: Common Stock · 61,538 shares Expires 2032-02-03 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the shares subject to the option will vest each year following Equity Grant Date on the same day of the month as the Equity Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over three (3) years. "Equity Grant Date" shall mean February 3, 2022. Read SEC document |
| December 09, 2021 Filed Dec 9, 2021 23:11 UTC | SelectQuote, Inc. SLQT · Entity 6791 | Exercise / conversionRestricted Stock Units · Derivative | 4,719 | $0.00 | $0.00 |
DisclosureSEC source: 0001794783-21-000173 · wf-form4_163909147551034.xml · derivative · entry 2 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.01 per share · 4,719 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents restricted stock units (RSUs) of SelectQuote, Inc. (the "Company") granted to Dr. Patel under the Company's 2020 Omnibus Incentive Plan. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock, $0.01 par value per share. F3 · derivative.exercise_date: The RSUs vest in full on the first anniversary of the grant date (the "Vesting Date"), subject to the recipient's continued service on the Company's Board of Directors as of the Vesting Date. F3 · derivative.expiration_date: The RSUs vest in full on the first anniversary of the grant date (the "Vesting Date"), subject to the recipient's continued service on the Company's Board of Directors as of the Vesting Date. Read SEC document |
| December 09, 2021 Filed Dec 9, 2021 23:11 UTC | SelectQuote, Inc. SLQT · Entity 6791 | Exercise / conversionCommon Stock, par value $0.01 per share | 4,719 | $0.00 | $0.00 |
DisclosureSEC source: 0001794783-21-000173 · wf-form4_163909147551034.xml · nonDerivative · entry 1 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 02:18 UTC | SelectQuote, Inc. SLQT · Entity 6791 | GrantRestricted Stock Units · Derivative | 7,849 | $0.00 | $0.00 |
DisclosureSEC source: 0001794783-21-000162 · wf-form4_163702909455962.xml · derivative · entry 1 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,849 Underlying: Common Stock, par value $0.01 per share · 7,849 shares Expires not disclosed F1 · security: Represents restricted stock units (RSUs) of SelectQuote, Inc. (the "Company") granted to Dr. Patel under the Company's 2020 Omnibus Incentive Plan. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock, $0.01 par value per share. F3 · derivative.exercise_date: The RSUs vest on the date of the Company's 2022 annual meeting of stockholders (the "Vesting Date"), subject to the recipient's continued service on the Company's Board of Directors as of the Vesting Date. F3 · derivative.expiration_date: The RSUs vest on the date of the Company's 2022 annual meeting of stockholders (the "Vesting Date"), subject to the recipient's continued service on the Company's Board of Directors as of the Vesting Date. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 11:15 UTC | Sigilon Therapeutics, Inc. SGTX · Entity 11481 | GrantStock Option (Right to Buy) · Derivative | 8,888 | $9.97 Strike: $9.97 | $88,613.36 |
DisclosureSEC source: 0001415889-21-003239 · form4-06282021_070608.xml · derivative · entry 1 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,888 Underlying: Common Stock · 8,888 shares Expires 2031-06-23 F1 · derivative.exercise_date: The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 100% on June 24, 2022. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 21:38 UTC | SelectQuote, Inc. SLQT · Entity 6791 | GrantStock Options · Derivative | 23,596 | $0.00 Strike: $22.77 | $0.00 |
DisclosureSEC source: 0000899243-20-033582 · doc4.xml · derivative · entry 2 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,596 Underlying: Common Stock, par value $0.01 per share · 23,596 shares Expires 2030-12-09 F4 · security: Represents non-qualified stock options of SelectQuote, Inc. granted to Dr. Patel under SelectQuote Inc.'s 2020 Omnibus Stock Incentive Plan. F5 · derivative.exercise_date: Stock options vest in three equal installments on the first three anniversaries of the grant date, subject to the award recipient's continued board service through the applicable vesting date. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 21:38 UTC | SelectQuote, Inc. SLQT · Entity 6791 | GrantRestricted Stock Units · Derivative | 4,719 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-033582 · doc4.xml · derivative · entry 1 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,719 Underlying: Common Stock, par value $0.01 per share · 4,719 shares Expires not disclosed F1 · security: Represents restricted stock units of SelectQuote, Inc. granted to Dr. Patel under SelectQuote Inc.'s 2020 Omnibus Stock Incentive Plan. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of SelectQuote, Inc. common stock, par value $0.01 per share. F3 · derivative.exercise_date: The restricted stock units vest on the first anniversary of the date of grant, subject to the award recipient's continued board service through the applicable vesting date. F3 · derivative.expiration_date: The restricted stock units vest on the first anniversary of the date of grant, subject to the award recipient's continued board service through the applicable vesting date. Read SEC document |
| January 22, 2019 Filed Jan 22, 2019 14:58 UTC | TESARO, Inc. TSRO · Entity 160894 | Disposition to issuerDirector Nonqualified Stock Option (right to buy) · Derivative | 7,209 | Not disclosed Strike: $46.89 | Not disclosed |
DisclosureSEC source: 0001123292-19-000172 · edgar.xml · derivative · entry 5 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,209 shares Expires 2028-06-01 F4 · price: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · price: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · derivative.exercise_date: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. Read SEC document |
| January 22, 2019 Filed Jan 22, 2019 14:58 UTC | TESARO, Inc. TSRO · Entity 160894 | Disposition to issuerDirector Nonqualified Stock Option (right to buy) · Derivative | 12,000 | Not disclosed Strike: $149.22 | Not disclosed |
DisclosureSEC source: 0001123292-19-000172 · edgar.xml · derivative · entry 4 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2027-06-01 F4 · price: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · price: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · derivative.exercise_date: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. Read SEC document |
| January 22, 2019 Filed Jan 22, 2019 14:58 UTC | TESARO, Inc. TSRO · Entity 160894 | Disposition to issuerDirector Nonqualified Stock Option (right to buy) · Derivative | 24,000 | Not disclosed Strike: $44.03 | Not disclosed |
DisclosureSEC source: 0001123292-19-000172 · edgar.xml · derivative · entry 3 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,000 shares Expires 2026-03-31 F4 · price: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · price: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · derivative.exercise_date: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. Read SEC document |
| January 22, 2019 Filed Jan 22, 2019 14:58 UTC | TESARO, Inc. TSRO · Entity 160894 | Disposition to issuerDirector Restricted Stock Units · Derivative | 4,052 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-19-000172 · edgar.xml · derivative · entry 2 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,052 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F3 · price: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. F3 · derivative.exercise_date: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. F3 · derivative.expiration_date: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. Read SEC document |
| January 22, 2019 Filed Jan 22, 2019 14:58 UTC | TESARO, Inc. TSRO · Entity 160894 | OtherCommon Stock | 2,757 | $75.00 | $206,775.00 |
DisclosureSEC source: 0001123292-19-000172 · edgar.xml · nonDerivative · entry 1 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement"). Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 21:07 UTC | TESARO, Inc. TSRO · Entity 160894 | GrantDirector Restricted Stock Units · Derivative | 4,052 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-038345 · a4.xml · derivative · entry 3 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,052 Underlying: Common Stock · 4,052 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of TESARO common stock. F4 · derivative.exercise_date: The RSUs vest on the earlier of the one-year anniversary of the date of grant and the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's board of directors. F4 · derivative.expiration_date: The RSUs vest on the earlier of the one-year anniversary of the date of grant and the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 21:07 UTC | TESARO, Inc. TSRO · Entity 160894 | GrantDirector Nonqualified Stock Option (right to buy) · Derivative | 7,209 | $0.00 Strike: $46.89 | $0.00 |
DisclosureSEC source: 0001104659-18-038345 · a4.xml · derivative · entry 2 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,209 Underlying: Common Stock · 7,209 shares Expires 2028-06-01 F2 · derivative.exercise_date: The option vests on the earlier of the one-year anniversary of the date of grant and the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 21:07 UTC | TESARO, Inc. TSRO · Entity 160894 | GrantCommon Stock | 1,226 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-038345 · a4.xml · nonDerivative · entry 1 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,757 F1 · shares: The Reporting Person has elected to receive common stock in lieu of cash for board retainers and fees otherwise payable in cash, and has elected to defer delivery of that common stock until the date that she separates from service on the Issuer's board of directors. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 22:15 UTC | TESARO, Inc. TSRO · Entity 160894 | GrantDirector Nonqualified Stock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $149.22 | $0.00 |
DisclosureSEC source: 0001104659-17-037538 · a4.xml · derivative · entry 2 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2027-06-01 F2 · derivative.exercise_date: The option vests on the earlier of the one-year anniversary of the date of grant and the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 22:15 UTC | TESARO, Inc. TSRO · Entity 160894 | GrantCommon Stock | 368 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-037538 · a4.xml · nonDerivative · entry 1 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,531 F1 · shares: The Reporting Person has elected to receive common stock in lieu of cash for board retainers and fees otherwise payable in cash. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.